Cargando…

Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody

Metastatic oral squamous cell carcinoma (SCC) displays a poor disease prognosis with a 5-year survival rate of 39%. Chemotherapy has emerged as the mainstream treatment against small clusters of cancer cells but poses more risks than benefits for metastatic cells due to the non-specificity and cytot...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Meng-Tsan, Sun, Ying-Sui, Keerthi, Murugan, Panda, Asit Kumar, Dhawan, Udesh, Chang, Yung-Hsiang, Lai, Chih-Fang, Hsiao, Michael, Wang, Huey-Yuan, Chung, Ren-Jei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746455/
https://www.ncbi.nlm.nih.gov/pubmed/35010011
http://dx.doi.org/10.3390/nano12010061
_version_ 1784630590141628416
author Tsai, Meng-Tsan
Sun, Ying-Sui
Keerthi, Murugan
Panda, Asit Kumar
Dhawan, Udesh
Chang, Yung-Hsiang
Lai, Chih-Fang
Hsiao, Michael
Wang, Huey-Yuan
Chung, Ren-Jei
author_facet Tsai, Meng-Tsan
Sun, Ying-Sui
Keerthi, Murugan
Panda, Asit Kumar
Dhawan, Udesh
Chang, Yung-Hsiang
Lai, Chih-Fang
Hsiao, Michael
Wang, Huey-Yuan
Chung, Ren-Jei
author_sort Tsai, Meng-Tsan
collection PubMed
description Metastatic oral squamous cell carcinoma (SCC) displays a poor disease prognosis with a 5-year survival rate of 39%. Chemotherapy has emerged as the mainstream treatment against small clusters of cancer cells but poses more risks than benefits for metastatic cells due to the non-specificity and cytotoxicity. To overcome these obstacles, we conjugated antibodies specific for matrix metalloproteinase-1 (MMP-1), a prognostic biomarker of SCC, to iron–gold bimetallic nanoparticles (FeAu NPs) and explored the capability of this complex to target and limit SSC cell growth via magnetic field-induced hyperthermia. Our results showed that 4.32 ± 0.79 nm sized FeAu NPs were superparamagnetic in nature with a saturation magnetization (Ms) of 5.8 emu/g and elevated the media temperature to 45 °C, confirming the prospect to deliver hyperthermia. Furthermore, conjugation with MMP-1 antibodies resulted in a 3.07-fold higher uptake in HSC-3 (human tongue squamous cell carcinoma) cells as compared to L929 (fibroblast) cells, which translated to a 5-fold decrease in cell viability, confirming SCC targeting. Finally, upon magnetic stimulation, MMP-1-FeAu NPs conjugate triggered 89% HSC-3 cellular death, confirming the efficacy of antibody-conjugated nanoparticles in limiting SCC growth. The synergistic effect of biomarker-specific antibodies and magnetic nanoparticle-induced hyperthermia may open new doors towards SCC targeting for improved disease prognosis.
format Online
Article
Text
id pubmed-8746455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87464552022-01-11 Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody Tsai, Meng-Tsan Sun, Ying-Sui Keerthi, Murugan Panda, Asit Kumar Dhawan, Udesh Chang, Yung-Hsiang Lai, Chih-Fang Hsiao, Michael Wang, Huey-Yuan Chung, Ren-Jei Nanomaterials (Basel) Article Metastatic oral squamous cell carcinoma (SCC) displays a poor disease prognosis with a 5-year survival rate of 39%. Chemotherapy has emerged as the mainstream treatment against small clusters of cancer cells but poses more risks than benefits for metastatic cells due to the non-specificity and cytotoxicity. To overcome these obstacles, we conjugated antibodies specific for matrix metalloproteinase-1 (MMP-1), a prognostic biomarker of SCC, to iron–gold bimetallic nanoparticles (FeAu NPs) and explored the capability of this complex to target and limit SSC cell growth via magnetic field-induced hyperthermia. Our results showed that 4.32 ± 0.79 nm sized FeAu NPs were superparamagnetic in nature with a saturation magnetization (Ms) of 5.8 emu/g and elevated the media temperature to 45 °C, confirming the prospect to deliver hyperthermia. Furthermore, conjugation with MMP-1 antibodies resulted in a 3.07-fold higher uptake in HSC-3 (human tongue squamous cell carcinoma) cells as compared to L929 (fibroblast) cells, which translated to a 5-fold decrease in cell viability, confirming SCC targeting. Finally, upon magnetic stimulation, MMP-1-FeAu NPs conjugate triggered 89% HSC-3 cellular death, confirming the efficacy of antibody-conjugated nanoparticles in limiting SCC growth. The synergistic effect of biomarker-specific antibodies and magnetic nanoparticle-induced hyperthermia may open new doors towards SCC targeting for improved disease prognosis. MDPI 2021-12-27 /pmc/articles/PMC8746455/ /pubmed/35010011 http://dx.doi.org/10.3390/nano12010061 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsai, Meng-Tsan
Sun, Ying-Sui
Keerthi, Murugan
Panda, Asit Kumar
Dhawan, Udesh
Chang, Yung-Hsiang
Lai, Chih-Fang
Hsiao, Michael
Wang, Huey-Yuan
Chung, Ren-Jei
Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title_full Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title_fullStr Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title_full_unstemmed Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title_short Oral Cancer Theranostic Application of FeAu Bimetallic Nanoparticles Conjugated with MMP-1 Antibody
title_sort oral cancer theranostic application of feau bimetallic nanoparticles conjugated with mmp-1 antibody
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746455/
https://www.ncbi.nlm.nih.gov/pubmed/35010011
http://dx.doi.org/10.3390/nano12010061
work_keys_str_mv AT tsaimengtsan oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT sunyingsui oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT keerthimurugan oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT pandaasitkumar oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT dhawanudesh oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT changyunghsiang oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT laichihfang oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT hsiaomichael oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT wanghueyyuan oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody
AT chungrenjei oralcancertheranosticapplicationoffeaubimetallicnanoparticlesconjugatedwithmmp1antibody